HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Zhejiang Jingxin Pharmaceutical (A/H Listing) - Growth Path Returns as VBP Will Subside

Pre-IPO SKG Health Technologies - The Industry, the Business and the Concerns

Pre-IPO Suzhou Zelgen Biopharmaceuticals (A/H Listing)- Valuation Relies on Innovative Drug Pipeline

Equity Capital Markets

Beijing Zhongke WengAI Science and Technology / Equity Capital Markets

Beijing Zhongke WengAI Science and Technology (ZKWAI HK)

Beijing Zhongke WengAI Science and Technology

<ul>
<li>Zhongke is different from the general large models on the market that mainly focus on C-end chatting/content generation. It is dedicated to creating an "AI decision-making brain" for enterprise/government clients.</li>
<li>Zhongke is known in the industry as the "Chinese replica" of the Palantir architecture. Zhongke's business strategy is "small but numerous" rather than Palantir's "large but deep".</li>
<li>For B-end clients, if they cannot see clear investment returns in short term, they tend to terminate cooperation or establish their own teams. These're structural challenges that Zhongke is facing.</li>
</ul>


Zhongke is different from the general large models on the market that mainly focus on C-end chatting/content generation. It is dedicated to creating an "AI decision-making brain" for enterprise/government clients.
Zhongke is known in the industry as the "Chinese replica" of the Palantir architecture. Zhongke's business strategy is "small but numerous" rather than Palantir's "large but deep".
For B-end clients, if they cannot see clear investment returns in short term, they tend to terminate cooperation or establish their own teams. These're structural challenges that Zhongke is facing.


Pre-IPO Beijing Zhongke WengAI Science and Technology (PHIP Update)-The Chinese Version of Palantir?